VBI Vaccines enters into license and collaboration agreement with Brii Biosciences
VBI Vaccines announced it a license and collaboration agreement with Brii Biosciences, a company committed to serving patients’ needs and improving public health in China, for development of a functional cure for the treatment of chronic hepatitis B infection, using VBI’s recombinant VBI-2601. December 06, 2018